医学
干细胞
造血干细胞移植
调理疗法
移植
髓系白血病
内科学
肿瘤科
微小残留病
养生
造血
外科
白血病
遗传学
生物
作者
Yogesh Jethava,Simona Sica,Bipin N. Savani,Francisco Socola,Madan Jagasia,Mohamad Mohty,Arnon Nagler,Andrea Bacigalupo
摘要
AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The conditioning regimens are classified as myeloablative conditioning, non-myeloablative or reduced intensity conditioning. Targeted radioimmunotherapy such as anti-CD45 antibody have also been added to the conditioning regimen in an attempt to improve tumor cell kill. Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age. Relapse post allo-HSCT remains an important issue, especially for patients who undergo transplant with residual or refractory disease. In these patients, pre- and post-transplant interventions need to be considered.
科研通智能强力驱动
Strongly Powered by AbleSci AI